The 2024-2025 Comirnaty injection still as follows:
"5.2 Myocarditis and Pericarditis
Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination."
"8.4 Pediatric Use
Safety and effectiveness of COMIRNATY in individuals 12 through 17 years of age is based on safety and effectiveness data in this age group and in adults.
The safety and effectiveness of COMIRNATY in individuals younger than 12 years of age have not been established."
Not a single word on cancer, SV40, DNA integration, immune dysfunction.
The 2024-2025 Comirnaty injection still as follows:
The safety and effectiveness of COMIRNATY in individuals younger than 12 years of age have not been established."
Not a single word on cancer, SV40, DNA integration, immune dysfunction.
The cull continues unabated.